This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease
Penner, Jacob,
Rupsingh, Raul,
Smith, Matthew,
Wells, Jennie L.,
Borrie, Michael J.,
Bartha, Robert
Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD). The purpose of this study was to determine if galantamine treatment would result in detectable hippocampal metabolite changes that correlated with changes in cognition, as measured by the Mini-Mental State Examination […]
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease
Zhong, Yuan,
Zheng, Xueli,
Miao, Ya,
Wan, Lili,
Yan, Hong,
Wang, Beiyun
Background: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer’s disease (AD).; Methods: A total of 110 Chinese AD patients participated in this study. Patients were treated with 5 to 10 mg of […]
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]
Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia
Liu, Xuan,
Zhang, Junjian,
Sun, Dong,
Fan, Yuanteng,
Zhou, Hongbin,
Fu, Binfang
Background: Selective serotonin reuptake inhibitors improve cognition in patients with stroke and increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. However, the effects of selective serotonin reuptake inhibitors on cognition and serum BDNF levels in patients with vascular dementia are largely unknown. We performed an open-label study to investigate the effects […]
Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand
Kulkantrakorn, Kongkiat,
Tanyakitpisal, Panas,
Towanabut, Somchai,
Dejthevaporn, Charungthai,
Rangseekajee, Poonsri,
Pongpakdee, Sunsanee,
Laptikultham, Somsak,
Rodprasert, Kritsada,
Setthawatcharawanich, Suwanna,
Thinkhamrop, Bandit
Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, […]
An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer’s Disease
Guo, Qihao,
Zhou, Yan,
Wang, Chao-Jih,
Huang, Young-Ming,
Lee, Yi-Ta,
Su, Muh-Hwan,
Lu, Jiahong
Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed […]
The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer’s disease treated in routine clinical practice in Spain
López-Pousa, S.,
Bermejo-Pareja, F.,
Frank, A.,
Hernández, F.,
León, T.,
Rejas-Gutiérrez, J.
Aims: Our aim was to perform a secondary analysis of a 12-month-long, non-blind, multi-centre prospective cost-of-illness study. The analysis assessed the effect of donepezil on cognitive functioning and the performance of patients with possible or probable Alzheimer’s disease, compared to that of other drugs for dementia.; Patients and Methods: A sample of 700 patients took […]